vs
雅培（ABT）与Encompass Health Corp（EHC）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是Encompass Health Corp的7.4倍（$11.5B vs $1.5B）。雅培净利率更高（15.5% vs 9.5%，领先6.0%）。Encompass Health Corp同比增速更快（9.9% vs 4.4%）。雅培自由现金流更多（$2.6B vs $116.7M）。过去两年Encompass Health Corp的营收复合增速更高（8.3% vs 7.2%）
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
Encompass Health Corp前身为Amcare及HealthSouth，总部位于美国阿拉巴马州伯明翰，是美国规模最大的住院康复服务提供商，在39个州及波多黎各拥有173家住院康复医院，为中风、神经系统疾病、心肺病症、脑损伤等患者提供专业康复诊疗服务。
ABT vs EHC — 直观对比
营收规模更大
ABT
是对方的7.4倍
$1.5B
营收增速更快
EHC
高出5.5%
4.4%
净利率更高
ABT
高出6.0%
9.5%
自由现金流更多
ABT
多$2.5B
$116.7M
两年增速更快
EHC
近两年复合增速
7.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $11.5B | $1.5B |
| 净利润 | $1.8B | $146.1M |
| 毛利率 | 57.0% | — |
| 营业利润率 | 19.6% | 16.7% |
| 净利率 | 15.5% | 9.5% |
| 营收同比 | 4.4% | 9.9% |
| 净利润同比 | -80.8% | 20.8% |
| 每股收益（稀释后） | $1.01 | $1.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTEHC
| Q4 25 | $11.5B | $1.5B | ||
| Q3 25 | $11.4B | $1.5B | ||
| Q2 25 | $11.1B | $1.5B | ||
| Q1 25 | $10.4B | $1.5B | ||
| Q4 24 | $11.0B | $1.4B | ||
| Q3 24 | $10.6B | $1.4B | ||
| Q2 24 | $10.4B | $1.3B | ||
| Q1 24 | $10.0B | $1.3B |
净利润ABTEHC
| Q4 25 | $1.8B | $146.1M | ||
| Q3 25 | $1.6B | $126.5M | ||
| Q2 25 | $1.8B | $142.1M | ||
| Q1 25 | $1.3B | $151.5M | ||
| Q4 24 | $9.2B | $120.9M | ||
| Q3 24 | $1.6B | $108.2M | ||
| Q2 24 | $1.3B | $114.1M | ||
| Q1 24 | $1.2B | $112.5M |
毛利率ABTEHC
| Q4 25 | 57.0% | — | ||
| Q3 25 | 55.4% | — | ||
| Q2 25 | 56.4% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 55.6% | — | ||
| Q1 24 | 55.2% | — |
营业利润率ABTEHC
| Q4 25 | 19.6% | 16.7% | ||
| Q3 25 | 18.1% | 14.9% | ||
| Q2 25 | 18.4% | 16.2% | ||
| Q1 25 | 16.3% | 16.4% | ||
| Q4 24 | 17.4% | 14.3% | ||
| Q3 24 | 17.5% | 13.6% | ||
| Q2 24 | 16.1% | 14.3% | ||
| Q1 24 | 13.9% | 13.6% |
净利率ABTEHC
| Q4 25 | 15.5% | 9.5% | ||
| Q3 25 | 14.5% | 8.6% | ||
| Q2 25 | 16.0% | 9.7% | ||
| Q1 25 | 12.8% | 10.4% | ||
| Q4 24 | 84.1% | 8.6% | ||
| Q3 24 | 15.5% | 8.0% | ||
| Q2 24 | 12.5% | 8.8% | ||
| Q1 24 | 12.3% | 8.5% |
每股收益（稀释后）ABTEHC
| Q4 25 | $1.01 | $1.43 | ||
| Q3 25 | $0.94 | $1.24 | ||
| Q2 25 | $1.01 | $1.39 | ||
| Q1 25 | $0.76 | $1.48 | ||
| Q4 24 | $5.26 | $1.18 | ||
| Q3 24 | $0.94 | $1.06 | ||
| Q2 24 | $0.74 | $1.12 | ||
| Q1 24 | $0.70 | $1.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.9B | $72.2M |
| 总债务越低越好 | $12.9B | $2.4B |
| 股东权益账面价值 | $52.1B | $2.4B |
| 总资产 | $86.7B | $7.1B |
| 负债/权益比越低杠杆越低 | 0.25× | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资ABTEHC
| Q4 25 | $8.9B | $72.2M | ||
| Q3 25 | $7.7B | $48.7M | ||
| Q2 25 | $7.3B | $99.1M | ||
| Q1 25 | $6.8B | $95.8M | ||
| Q4 24 | $8.0B | $85.4M | ||
| Q3 24 | $7.8B | $147.8M | ||
| Q2 24 | $7.2B | $154.4M | ||
| Q1 24 | $6.7B | $134.4M |
总债务ABTEHC
| Q4 25 | $12.9B | $2.4B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | $14.1B | $2.4B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.7B | ||
| Q1 24 | — | $2.7B |
股东权益ABTEHC
| Q4 25 | $52.1B | $2.4B | ||
| Q3 25 | $51.0B | $2.4B | ||
| Q2 25 | $50.6B | $2.3B | ||
| Q1 25 | $48.8B | $2.2B | ||
| Q4 24 | $47.7B | $2.1B | ||
| Q3 24 | $39.8B | $2.0B | ||
| Q2 24 | $39.3B | $1.8B | ||
| Q1 24 | $38.8B | $1.7B |
总资产ABTEHC
| Q4 25 | $86.7B | $7.1B | ||
| Q3 25 | $84.2B | $6.9B | ||
| Q2 25 | $84.0B | $6.8B | ||
| Q1 25 | $81.4B | $6.6B | ||
| Q4 24 | $81.4B | $6.5B | ||
| Q3 24 | $74.4B | $6.5B | ||
| Q2 24 | $73.0B | $6.4B | ||
| Q1 24 | $72.5B | $6.2B |
负债/权益比ABTEHC
| Q4 25 | 0.25× | 1.00× | ||
| Q3 25 | — | 1.01× | ||
| Q2 25 | — | 1.02× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | 0.30× | 1.14× | ||
| Q3 24 | — | 1.20× | ||
| Q2 24 | — | 1.46× | ||
| Q1 24 | — | 1.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $346.0M |
| 自由现金流经营现金流 - 资本支出 | $2.6B | $116.7M |
| 自由现金流率自由现金流/营收 | 22.9% | 7.6% |
| 资本支出强度资本支出/营收 | 6.0% | 14.8% |
| 现金转化率经营现金流/净利润 | 1.87× | 2.37× |
| 过去12个月自由现金流最近4个季度 | $7.4B | $439.2M |
8季度趋势，按日历期对齐
经营现金流ABTEHC
| Q4 25 | $3.3B | $346.0M | ||
| Q3 25 | $2.8B | $270.8M | ||
| Q2 25 | $2.0B | $270.2M | ||
| Q1 25 | $1.4B | $288.6M | ||
| Q4 24 | $2.9B | $278.8M | ||
| Q3 24 | $2.7B | $267.8M | ||
| Q2 24 | $2.0B | $217.4M | ||
| Q1 24 | $1.0B | $238.8M |
自由现金流ABTEHC
| Q4 25 | $2.6B | $116.7M | ||
| Q3 25 | $2.3B | $83.7M | ||
| Q2 25 | $1.5B | $113.3M | ||
| Q1 25 | $933.0M | $125.5M | ||
| Q4 24 | $2.1B | $80.1M | ||
| Q3 24 | $2.1B | $120.3M | ||
| Q2 24 | $1.4B | $60.5M | ||
| Q1 24 | $627.0M | $99.4M |
自由现金流率ABTEHC
| Q4 25 | 22.9% | 7.6% | ||
| Q3 25 | 20.2% | 5.7% | ||
| Q2 25 | 13.9% | 7.8% | ||
| Q1 25 | 9.0% | 8.6% | ||
| Q4 24 | 19.6% | 5.7% | ||
| Q3 24 | 20.2% | 8.9% | ||
| Q2 24 | 13.8% | 4.6% | ||
| Q1 24 | 6.3% | 7.6% |
资本支出强度ABTEHC
| Q4 25 | 6.0% | 14.8% | ||
| Q3 25 | 4.4% | 12.7% | ||
| Q2 25 | 4.5% | 10.8% | ||
| Q1 25 | 4.7% | 11.2% | ||
| Q4 24 | 6.6% | 14.1% | ||
| Q3 24 | 5.2% | 10.9% | ||
| Q2 24 | 5.1% | 12.1% | ||
| Q1 24 | 4.0% | 10.6% |
现金转化率ABTEHC
| Q4 25 | 1.87× | 2.37× | ||
| Q3 25 | 1.70× | 2.14× | ||
| Q2 25 | 1.15× | 1.90× | ||
| Q1 25 | 1.07× | 1.90× | ||
| Q4 24 | 0.31× | 2.31× | ||
| Q3 24 | 1.64× | 2.48× | ||
| Q2 24 | 1.51× | 1.91× | ||
| Q1 24 | 0.84× | 2.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABT
暂无分部数据
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
